May 20, 2024 02:14 PM EDTUpdated 02:39 PM
Pharma
FDA+

PTC's mus­cu­lar dy­s­tro­phy drug Translar­na to get an­oth­er re­view in the EU

Katherine Lewin

News Reporter

The Eu­ro­pean Com­mis­sion made the rare de­ci­sion Mon­day not to adopt the neg­a­tive opin­ion of the Eu­ro­pean Med­i­cines Agency’s Com­mit­tee for Med­i­c­i­nal Prod­ucts for Hu­man …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Au­toim­mune CAR-T da­ta dump: Kyver­na, Ca­balet­ta shares fall af­ter un­veil­ing ear­ly-stage re­sults

Rare pe­di­atric dis­ease vouch­ers face un­cer­tain fu­ture af­ter Sep­tem­ber

Ex­clu­sive: For­mer Mer­ck sci­en­tists raise $85M to map and drug pro­tein in­ter­ac­tions in can­cer and au­toim­mune dis­ease

Gilead can­cer drug ma­grolimab showed wor­ry­ing trends around death

Stephen Squin­to talks writ­ing checks and next-gen obe­si­ty drugs as JP Mor­gan clos­es first $500M+ biotech fund

sponsored

De-risk­ing the pa­tient jour­ney in cell ther­a­pies: Six key con­sid­er­a­tions

A service from the Financial Times